Vincerx Pharma, Inc.

VINC

US92731L1061

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 01:30:00 01/06/2024 am IST			5-day change	1st Jan Change
0.631 ^USD	-8.59%		-7.72%	-46.53%

26/04	Tech Rally Boosts Exchange-Traded Funds, Equity Futures Pre-Bell Friday	MT
26/04	Vincerx Pharma Prices Public Offering of Shares, Warrants	MT

Vincera Pharma, Inc. has Changed its Name to Vincerx, Inc

January 08, 2021 at 02:31 am IST

Vincera Pharma, Inc. changed its name to Vincerx, Inc.

Latest news about Vincerx Pharma, Inc.

Tech Rally Boosts Exchange-Traded Funds, Equity Futures Pre-Bell Friday	26/04	MT
Vincerx Pharma Prices Public Offering of Shares, Warrants	26/04	MT
Wall Street Set to Open Slightly Higher as Investors Await Wednesday's Inflation Data	09/04	MT
Top Premarket Decliners	09/04	MT
Investors Eye Wednesday Inflation Data as US Futures Tread Water Tuesday Pre-Bell	09/04	MT
Vincerx Pharma, Inc. Presents Positive Preliminary Phase 1 Data for Vip236 and Updates on Pipeline Progress At the American Association for Cancer Research Annual Meeting 2024	09/04	CI
Vincerx Pharma, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	30/03	CI
North American Morning Briefing : Tech in Focus on -2-	25/03	DJ
Vincerx Pharma Shares Jump After Results of Blood Cancer Treatment Trial	09/01	MT
Top Premarket Gainers	08/01	MT
Vincerx Pharma, Inc. Announces Compelling Clinical Efficacy of Enitociclib in Combination with Venetoclax and Prednisone in Lymphoma	08/01	CI
Vincerx Pharma, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	14/11	CI
Sector Update: Health Care Stocks Mixed Premarket Thursday	14/23/14	MT
Vincerx Pharma Doses First Patient in Early-Stage Trial of Blood Cancer Drug Candidate	14/23/14	MT
Sector Update: Health Care Stocks Slipping Late Afternoon	23/23/23	MT
Sector Update: Health Care Stocks Lower in Afternoon Trading	22/23/22	MT
Vincerx Pharma Says US FDA Approved Phase 1 Trial for Potential Acute Myeloid Leukemia Treatment	22/23/22	MT
Vincerx Pharma Shares Jump 8% Premarket After FDA Clearance for Clinical Trial	22/23/22	DJ
Vincerx Pharma, Inc. Announces FDA Clearance of IND for VIP943	22/23/22	CI
Vincerx Pharma, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	07/23/07	CI
Vincerx Pharma, Inc.(NasdaqCM:VINC) dropped from Russell 3000E Value Index	23/23/23	CI
Vincerx Pharma, Inc.(NasdaqCM:VINC) dropped from Russell Microcap Index	23/23/23	CI
Vincerx Pharma, Inc.(NasdaqCM:VINC) dropped from Russell Microcap Value Index	23/23/23	CI
Vincerx Pharma, Inc.(NasdaqCM:VINC) dropped from Russell 3000E Index	23/23/23	CI
Vincerx Pharma, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	12/23/12	CI

Vincerx Pharma, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing differentiated and novel therapies to address the unmet medical needs of patients with cancer. It has a next generation bioconjugation platform, called VersAptx. The VersAptx platform is a versatile and adaptable, next generation bioconjugation platform. Its product candidates include VIP943 (CD123-KSPi), VIP924 (CXCR5-KSPi), VIP236, and Enitociclib (P-TEFb/CDK9 inhibitor). VIP943 is a potential anti-CD123 ADC created with its VersAptx Platform. It consists of an anti-CD123 antibody, a novel legumain-cleavable linker, and a KSPi payload enhanced with its CellTrapper technology. Enitociclib is a selective CDK9 inhibitor. Enitociclib effectively blocks P-TEFb-mediated activation of RNA polymerase II, preventing transcription of MCL1 and MYC, proteins associated with poor prognosis in various types of cancer.

Sector

Biotechnology & Medical Research

Calendar

08/08/2024 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

0.631 USD

Average target price

9 USD

Spread / Average Target

+1,326.31%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
VINCERX PHARMA, INC.	-46.53%	1.86Cr
VERTEX PHARMACEUTICALS INCORPORATED	+11.91%	12TCr
REGENERON PHARMACEUTICALS, INC.	+11.60%	11TCr
BIONTECH SE	-4.68%	2.43TCr
ARGENX SE	-0.82%	2.2TCr
GENMAB A/S	-10.12%	1.82TCr
WUXI APPTEC CO., LTD.	-42.12%	1.64TCr
BEIGENE, LTD.	-17.47%	1.56TCr
NEUROCRINE BIOSCIENCES, INC.	+2.77%	1.36TCr
SAREPTA THERAPEUTICS, INC.	+34.58%	1.23TCr

Bio Therapeutic Drugs

Vincerx Pharma, Inc.

Equities

VINC

US92731L1061

Biotechnology & Medical Research

Vincera Pharma, Inc. has Changed its Name to Vincerx, Inc

Latest news about Vincerx Pharma, Inc.

Chart Vincerx Pharma, Inc.

Company Profile

Income Statement Evolution

Analysts' Consensus

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Bio Therapeutic Drugs